Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RBP4 | P02753 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 7/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | CCR4 | P51679 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.38 |
| ▸ | FNTA | P49354 | 1/20 | 0.38 |
| ▸ | FNTB | P49356 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24792587 | 1.00 | RBP4 (0.42) | RBP4USP2HPGDMRGPRX4ANO1 | |
| SCHEMBL29826227 | 0.91 | FNTA (0.44) | USP2HPGDCNR1KMT2AGPR119 | |
| SCHEMBL24791720 | 0.87 | MRGPRX4 (0.51) | RBP4USP2HPGDMRGPRX4CNR1 | |
| SCHEMBL29826482 | 0.81 | USP2 (0.43) | USP2HPGDMRGPRX4KMT2AGPR119 | |
| SCHEMBL19833905 | 0.81 | RBP4 (0.61) | RBP4HPGDCNR1KMT2ATSHR | |
| SCHEMBL30056362 | 0.80 | KMT2A (0.42) | RBP4USP2HPGDMRGPRX4CNR1 | |
| SCHEMBL24792585 | 0.80 | KMT2A (0.42) | RBP4USP2HPGDMRGPRX4CNR1 | |
| SCHEMBL29826054 | 0.79 | TSHR (0.42) | USP2HPGDMRGPRX4KMT2AGPR119 | |
| SCHEMBL29826215 | 0.79 | CYP2C9 (0.44) | GPR119TSHR | |
| SCHEMBL29826196 | 0.79 | USP2 (0.40) | USP2HPGDMRGPRX4KMT2AGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4461355-A2 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-11-13 | — | — | EP | disclosed |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2024-08-08 | — | — | US | disclosed |
| EP-4334304-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | Carmot Therapeutics, Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. | 2022-12-15 | — | — | US | disclosed |
| WO-2022235717-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | CARMOT THERAPEUTICS, INC. (US) | 2022-11-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220396569-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | RBP4 866/4885USP2 3327/4885HPGD 2673/4885 |
| US-20240262811-A1 | BENZIMIDAZOYL GLP-1 RECEPTOR AGONISTS, PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME, AND METHODS FOR THEIR USE | GLP1R, GIPR, GCGR | RBP4 866/4885USP2 3327/4885HPGD 2673/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.